Estrogen Receptor Signaling in Breast Cancer
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Estrogen receptor (ER) signaling is a critical regulator of cell proliferation, differentiation, and survival in breast cancer (BC) and other hormone-sensitive cancers. In this review, we explore the mechanism of ER-dependent downstream signaling in BC and the role of estrogens as growth factors necessary for cancer invasion and dissemination. The significance of the clinical implications of ER signaling in BC, including the potential of endocrine therapies that target estrogens’ synthesis and ER-dependent signal transmission, such as aromatase inhibitors or selective estrogen receptor modulators, is discussed. As a consequence, the challenges associated with the resistance to these therapies resulting from acquired ER mutations and potential strategies to overcome them are the critical point for the new treatment strategies’ development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
Current and future burden of breast cancer: Global statistics for 2020 and 2040
Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.08.010 · Cited by 3,411
Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J., & Cardoso, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0111-2 · Cited by 3,024
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871 · cited 1×
“The promoters of genes implicated in particular biochemical pathways are methylated in a number of cancers, including breast cancer (reviewed in: [157]).”
BackgroundA signature motif in transcriptional co-activators mediates binding to nuclear receptors
Heery, D. M., Kalkhoven, E., Hoare, S., & Parker, M. G. (1997) · Nature · doi:10.1038/42750 · Cited by 2,128 · cited 1×
“The coregulators’ complexes are recruited by the ER via a characteristic, conserved LxxLL motif [104] (L, leucine; x, any amino acid) that acts on the LBD. Coregula-tors are often associated with enzymes such as methyltransferases, acetylases/deacetylases, phosphokinases, ubiquitin ligases, and…”
BackgroundEstrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065 · cited 1×
“The effect of estrogens on the cardiovascular system may be protective, as shown by several studies, including large-scale clinical trials [27–29], but have also been associated with the risk of coronary heart disease [30].”
BackgroundEstrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Turner, N. C., Slamon, D. J., Ro, J., Bondarenko, I., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810527 · Cited by 1,276 · cited 1×
“However, the success of these treatments is still limited due to the acquired patients’ resistance to these inhibitors [150].”
BackgroundJin, Q., Yu, L., Wang, L., Zhang, Z., Kasper, L. H., Lee, J., Wang, C., Brindle, P. K., Dent, S. Y. R., & Ge, K. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.318 · Cited by 877
The emerging complexity of protein ubiquitination
Komander, D. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370937 · Cited by 821
Vascular effects of early versus late postmenopausal treatment with estradiol
Hodis, H. N., Mack, W. J., Henderson, V. W., Shoupe, D., Budoff, M. J., Hwang-Levine, J., Li, Y., Feng, M., Dustin, L., Kono, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505241 · Cited by 779 · cited 1×
“The effect of estrogens on the cardiovascular system may be protective, as shown by several studies, including large-scale clinical trials [27–29], but have also been associated with the risk of coronary heart disease [30].”
BackgroundBoth corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3
Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J. M., Qin, J., & Wong, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4342 · Cited by 629
The SMRT and N-CoR Corepressors Are Activating Cofactors for Histone Deacetylase 3
Guenther, M. G., Barak, O., & Lazar, M. A. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.18.6091-6101.2001 · Cited by 611
The amphioxus genome illuminates vertebrate origins and cephalochordate biology
Holland, L. Z., Albalat, R., Azumi, K., Benito-Gutiérrez, È., Blow, M. J., Bronner-Fraser, M., Brunet, F., Butts, T., Candiani, S., Dishaw, L. J., et al. (2008) · Genome Research · doi:10.1101/gr.073676.107 · Cited by 512 · cited 1×
“Interestingly, the ER homologs have been identified in amphioxus [36,37], mollusks [38,39], and annelids [40].”
BackgroundEstrogen Receptors and the Metabolic Network
Barros, R. P. A., & Gustafsson, J.-Å. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.08.005 · Cited by 458 · cited 1×
“These hormones play a significant role in the proliferation and growth of cells associated with reproduction and have a myriad of other cellular functions; for instance, carbohydrate and lipid metabolism, and the regulation of energy homeostasis [17,24].”
BackgroundYardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
Safe, S., & Kim, K. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0103 · Cited by 368
Filardo, E. J., & Thomas, P. (2012) · Endocrinology · doi:10.1210/en.2012-1061 · Cited by 366 · cited 1×
“The ER family includes the nuclear ER (nER) and G protein-coupled estrogen receptor 1 (GPER1) [33]. nER is characterized by conserved domain structures, such as the DNA-binding domain (DBD) and the ligand-binding domain (LBD) [34].”
BackgroundSpoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., et al. (2016) · Nature Communications · doi:10.1038/ncomms11579 · Cited by 309
Steroidogenesis: Unanswered Questions
Miller, W. L. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.09.002 · Cited by 226
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205
Effects of estrogen on breast cancer development: Role of estrogen receptor independent mechanisms
Yue, W., Wang, J., Li, Y., Fan, P., Liu, G., Zhang, N., Conaway, M., Wang, H., Korach, K. S., Bocchinfuso, W., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25207 · Cited by 196 · cited 1×
“ERs are activated by estrogens and play important roles in the development of several cancers; in particular, breast [14], endometrial [15], and ovarian cancers [16].”
BackgroundAn Acetylation Switch Modulates the Transcriptional Activity of Estrogen-Related Receptor α
Wilson, B. J., Tremblay, A. M., Deblois, G., Sylvain-Drolet, G., & Giguère, V. (2010) · Molecular Endocrinology · doi:10.1210/me.2009-0441 · Cited by 192 · cited 1×
“For example, the p300/CBP acetylates elements of the basal transcription machinery and interacts with other HATs, such as PCAF [76–78].”
BackgroundZhang, G., Wang, Y., Chen, B., Guo, L., Cao, L., Ren, C., Wen, L., Li, K., Jia, M., Li, C., et al. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.04.23 · Cited by 66 · cited 2×
“Receptor Mutations These so-called mutational cancer diver genes have been reviewed in detail by colleagues identi [195] characterized and colleagues [13] summarized driver mutations in the context of BC subtypes.”
Background
Metadata
- Authors
- Miziak, P., Baran, M., Błaszczak, E., Przybyszewska-Podstawka, A., Kałafut, J., Smok-Kalwat, J., Dmoszyńska-Graniczka, M., Kiełbus, M., & Stepulak, A.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2023-09-23
- Volume
- 15
- Issue
- 19
- Pages
- 4689
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W4386996041
- Cited by
- 207
- References
- 27
- FWCI
- 30.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.